Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Exscientia Plc (EXAI)
NASDAQ:EXAI
Holding EXAI?
Track your performance easily
EXAI Stock Chart & Stats
Day’s Range$4.49 - $4.85
52-Week Range― - ―
Previous Close$4.69
Volume1.51M
Average Volume (3M)N/A
Market Cap
$632.93M
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding125,702,396
10 Day Avg. Volume1,171,634
30 Day Avg. Volume715,998
Standard Deviation0.19
R-Squared0.05
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.71
Price to Sales (P/S)22.62
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$5.35Price Target Upside10.54% Upside
Rating ConsensusHold
Number of Analyst Covering2
Exscientia Plc News
PremiumCompany Announcements
Exscientia and Recursion Merge to Revolutionize Drug Discovery
PremiumCompany Announcements
Recursion and Exscientia Merger Approved by ShareholdersPremiumCompany Announcements
Exscientia Plc Gains Strong Shareholder Support
PremiumCompany Announcements
Exscientia Plc Faces Financial Challenges Amid Rising CostsBulls Say, Bears Say
Bulls Say
Innovative Drug DiscoveryExscientia's AI-driven drug discovery platform incorporates live patient sample data and active machine learning to maximize the information gained from a given inquiry.
Promising Clinical PipelineCombining the pipelines and partnership portfolios of Exscientia and Recursion positions the combined entity for up to 10 clinical readouts and approximately $200M in potential milestone payments.
Strategic Merger BenefitsThe merger is a solid outcome for Exscientia that expands the resources at their disposal and adds multiple clinical-stage assets to their portfolio.
Bears Say
Financial PerformanceReturn on Equity for EXAI over the trailing twelve months is -34.98%.
Stock DowngradeThe stock rating for EXAI has been downgraded to Equal Weight following the announced all-stock transaction with Recursion Pharmaceuticals.
Transaction RisksRisks associated with EXAI include competition in the AI space, potential negative clinical data updates, and the possibility of the transaction with Recursion Pharma not closing.
---
Ownership Overview
―
Insiders
0.03% Mutual Funds
― Other Institutional Investors
99.97% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
EXAI FAQ
What was Exscientia Plc’s price range in the past 12 months?
Currently, no data Available
What is Exscientia Plc’s market cap?
Currently, no data Available
When is Exscientia Plc’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Exscientia Plc’s earnings last quarter?
Currently, no data Available
Is Exscientia Plc overvalued?
According to Wall Street analysts Exscientia Plc’s price is currently Undervalued.
Does Exscientia Plc pay dividends?
Exscientia Plc does not currently pay dividends.
What is Exscientia Plc’s EPS estimate?
Exscientia Plc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Exscientia Plc have?
Currently, no data Available
What happened to Exscientia Plc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Exscientia Plc?
Among the largest hedge funds holding Exscientia Plc’s share is Platinum Investment Management. It holds Exscientia Plc’s shares valued at 7M.
---
Exscientia Plc Stock Smart Score
Company Description
Exscientia Plc
Exscientia PLC is an artificial intelligence-driven pharma tech company committed to discovering, designing, and developing drugs. Its patient-first AI process is comprised of Precision Target, Precision Design, Precision Experiment, and Precision Medicine. Its revenue is generated from Service fees related to drug discovery collaboration agreements it is utilizing its proprietary technology to develop novel Intellectual Property (IP); and Licensing fees related to drug discovery agreements.
---
EXAI Stock 12 Month Forecast
Average Price Target
$5.35
▲(10.54% Upside)
Technical Analysis
---